Over the past few months, CCI has been considering establishing a position in Teva pharmaceuticals. Rational for investing in Teva can be found in the following article.
Seeking Alpha - Teva Time
This article suggests that selling naked puts might be a viable approach for investors just starting to consider buying this stock (as a low risk ay to get a better price.) CCI had taken this approach when the stock was down in April and the stock rebounded, so CCI has already pocketed $2.32/share in option premium using this approach. With that gain in the bank, CCI bough an initial lot at a price of $48.01 after commissions earlier this week and will be looking for an options based approach to control a second lot of shares in the near future.